These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 15453921)
1. Rituximab Improves Rate and Duration of Chemotherapy-Induced Remissions in Indolent and Aggressive Non-Hodgkin's Lymphoma. Gibson AD Clin Lymphoma; 2004 Sep; 5(2):81-3. PubMed ID: 15453921 [No Abstract] [Full Text] [Related]
2. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Coiffier B Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461 [TBL] [Abstract][Full Text] [Related]
3. Rituximab in combination with platinum-containing chemotherapy in patients with relapsed or primary refractory diffuse large B-cell lymphoma. Bieker R; Kessler T; Berdel WE; Mesters RM Oncol Rep; 2003; 10(6):1915-7. PubMed ID: 14534718 [TBL] [Abstract][Full Text] [Related]
4. Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Lemieux B; Bouafia F; Thieblemont C; Hequet O; Arnaud P; Tartas S; Traulle C; Salles G; Coiffier B Hematol J; 2004; 5(6):467-71. PubMed ID: 15570286 [TBL] [Abstract][Full Text] [Related]
5. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Coiffier B Semin Oncol; 2002 Apr; 29(2 Suppl 6):18-22. PubMed ID: 12040530 [TBL] [Abstract][Full Text] [Related]
6. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation. Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894 [TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Cvetković RS; Perry CM Drugs; 2006; 66(6):791-820. PubMed ID: 16706552 [TBL] [Abstract][Full Text] [Related]
9. A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Brandt L; Kimby E; Nygren P; Glimelius B; Acta Oncol; 2001; 40(2-3):213-23. PubMed ID: 11441933 [TBL] [Abstract][Full Text] [Related]
10. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Vose JM; Link BK; Grossbard ML; Czuczman M; Grillo-Lopez A; Fisher RI Leuk Lymphoma; 2005 Nov; 46(11):1569-73. PubMed ID: 16236611 [TBL] [Abstract][Full Text] [Related]
11. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Martinelli G; Laszlo D; Bertolini F; Pastano R; Mancuso P; Calleri A; Vanazzi A; Santoro P; Cavalli F; Zucca E Br J Haematol; 2003 Oct; 123(2):271-7. PubMed ID: 14531908 [TBL] [Abstract][Full Text] [Related]
12. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. Economopoulos T; Fountzilas G; Pavlidis N; Kalantzis D; Papageorgiou E; Christodoulou C; Hamilos G; Nicolaides C; Dimopoulos M Hematol J; 2003; 4(2):110-5. PubMed ID: 12750729 [TBL] [Abstract][Full Text] [Related]
13. Rituximab combined with CHOP for successful treatment of aggressive recurrent, pediatric B-cell large cell non-Hodgkin's lymphoma. Jetsrisuparb A; Wiangnon S; Komvilaisak P; Kularbkaew C; Yutanawiboonchai W; Mairieng E J Pediatr Hematol Oncol; 2005 Apr; 27(4):223-6. PubMed ID: 15838396 [TBL] [Abstract][Full Text] [Related]
14. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma. Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308 [No Abstract] [Full Text] [Related]
15. Rituximab: ongoing and future clinical development. Grillo-López AJ; Hedrick E; Rashford M; Benyunes M Semin Oncol; 2002 Feb; 29(1 Suppl 2):105-12. PubMed ID: 11842397 [TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab. Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996 [TBL] [Abstract][Full Text] [Related]
17. Factors predicting the response to rituximab in indolent lymphoma. Lee D Clin Lymphoma; 2003 Jun; 4(1):19-21. PubMed ID: 12837149 [No Abstract] [Full Text] [Related]
18. Diffuse aggressive lymphoma. Fisher RI; Miller TP; O'Connor OA Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685 [TBL] [Abstract][Full Text] [Related]